EMA Authorised: Shingrix (recombinant varicella zoster virus glycoprotein E) — GlaxoSmithKline Biologicals S.A.

View source ↗

Summary

The European Medicines Agency authorised Shingrix, a recombinant varicella zoster virus glycoprotein E vaccine by GlaxoSmithKline Biologicals S.A., for the prev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Status: Authorised. Therapeutic area: Herpes Zoster. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 12/02/2026